Tirzepatide Shows Promise for Alcohol Use Disorder Treatment in Preclinical Study
核心洞察
Tirzepatide, the active ingredient in Mounjaro, reduced voluntary alcohol consumption by more than half in animal models and prevented relapse-like drinking behaviors.
The dual GIP/GLP-1 receptor (搜索) agonist appears to work by attenuating alcohol-induced dopamine effects in the brain's reward system, particularly in the lateral septum (搜索) region.
Researchers identified changes in histone-related proteins in the lateral septum (搜索), suggesting potential long-term biological mechanisms underlying the drug's effects on addiction pathways.
Researchers at the University of Gothenburg have demonstrated that tirzepatide, the active ingredient in the diabetes and weight-loss drug Mounjaro, significantly reduces alcohol consumption and prevents relapse-like behaviors in animal models. The findings, published in eBioMedicine, represent the first study to examine tirzepatide's effects on alcohol use disorder (搜索) and provide new insights into how this class of medications may influence the brain's reward system.
Dramatic Reduction in Alcohol Consumption
In the preclinical study, voluntary alcohol consumption fell by more than half in animals treated with tirzepatide compared to control groups (P < 0.001). The drug demonstrated effectiveness across multiple drinking paradigms, including binge-like drinking (P < 0.01) and relapse-like drinking behaviors (P < 0.001).
"We observed clear and robust reductions in long-term alcohol consumption, binge-like drinking, and relapse-like drinking in both male and female animals," said Christian Edvardsson, a doctoral student in pharmacology at the Sahlgrenska Academy, University of Gothenburg. "What makes this study particularly compelling is that it also provides new insight into how this class of drugs may influence the brain's reward system."
The drug's effects were sustained during repeated administration, and notably, after a period without alcohol, treated animals did not exhibit the typical increase in drinking associated with relapse. Instead, their consumption decreased compared with earlier levels.
Neurobiological Mechanisms
The research team found that tirzepatide attenuated alcohol-induced effects on dopamine (P < 0.001), a key neurotransmitter in the brain's reward system that contributes to alcohol's reinforcing properties. The effect appears to be mediated, at least in part, through the lateral septum (搜索), a brain region linked to motivation, reward, and relapse in both animals and humans.
Tirzepatide induced sustained synaptic depression in the lateral septum (搜索) (P < 0.05), suggesting a potential neural substrate for its effects. The researchers also identified changes in histone-related proteins in this region (P < 0.05), which influence whether genes are switched on or off. Alterations in these proteins have previously been associated with substance use and addiction.
Dual Mechanism Advantage
Tirzepatide represents the first medication to act as a dual agonist at receptors for the satiety hormones GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). This dual mechanism may provide advantages over single-target approaches like semaglutide, which targets only GLP-1 receptors.
The drug is already approved for the treatment of type 2 diabetes (搜索) and is widely used in clinical practice. Its extensively studied safety profile may facilitate future research into its potential role in alcohol use disorder (搜索) treatment.
Comprehensive Study Design
The study was conducted in collaboration with colleagues at the Medical University of South Carolina and combined behavioral assays, alcohol intake paradigms, and molecular analyses. The research team examined locomotor activity, conditioned place preference, intermittent access two-bottle choice paradigms, drinking in the dark protocols, and the alcohol deprivation effect.
Beyond its effects on alcohol-related behaviors, tirzepatide also affected metabolic parameters including body weight (P < 0.001), adipose tissue mass (P < 0.01), hepatic triglycerides (P < 0.01), and circulating pro-inflammatory cytokines (P < 0.05).
Clinical Implications
"This is not yet a new treatment for alcohol use disorder (搜索)," cautioned Elisabet Jerlhag Holm, Professor of Pharmacology at the Sahlgrenska Academy, University of Gothenburg. "But the findings reinforce the view that drugs targeting these neural systems may be relevant to investigate further as potential treatment options."
The findings offer a possible neurobiological explanation for earlier observations that similar medications can reduce alcohol consumption and craving. Given tirzepatide's established clinical use and the consistency of effects observed in this study, the results support further investigation for treating alcohol use disorder (搜索) and associated complications.